Affiliation:
1. Department of Paramedical and Allied Health Sciences, Biodiversity and Environmental Studies Research Centre, Midnapore City College, Kuturiya, Bhadutala, Paschim Medinipur- 721129, West Bengal, India
Abstract
Visceral leishmaniasis (VL) is a neglected tropical disease, and this review has summarized the current treatment scenario and its prospects. It also highlights alternative approaches used by research groups in India and around the world to develop cutting-edge and potent anti-leishmanial treatments. Even though numerous medications could be utilized to treat VL, the limitations of current treatments including their toxicity, cost, route of administration, and duration of doses, have contributed to the emergence of resistance. Combination therapy might be a better option due to its shorter duration, easier route of administration, and ability to extend the lifespan of individual drugs. However, there is a risk of not delivering both the drugs to the target site together, which can be overcome by the liposomal entrapment of those drugs and at a time knock an opportunity to reduce the dosage of amphotericin B if the combination drug provides a synergistic effect with it. Therefore, this review presents a novel strategy to fight against VL by introducing dual drug-loaded liposomes.
Reference114 articles.
1. Leishmania donovani transmission cycle associated with human infection, Phlebotomus alexandri sand flies, and hare blood meals, Israel;Studentsky;Emerg Infect Dis,2023
2. Insights into the drug screening approaches in leishmaniasis;Gopu;Int Immunopharmacol,2023
3. A report on visceral leishmaniasis as neglected tropical disease
4. Lymphatic filariasis and visceral leishmaniasis coinfection: A review on their epidemiology, therapeutic, and immune responses;Vikas;Acta Trop,2021
5. The status of combination therapy for visceral leishmaniasis: An updated review;van Griensven;Lancet Infect Dis,2024